SBIR Phase II: Point of Care Metabolic Measurement

Sequitur Health Corp, Scottsdale AZ

Investigators

Abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project will be to improve diagnosis of specific disorders with metabolic measurement of whole blood. It will be used at the point of care as a rapid diagnostic for newborn screening (~3.9 million babies born annually in the U.S.) and as a daily monitoring system for people living with specific diseases (~600,000 people in the U.S.). This will improve clinical outcomes at reduced cost of care. This Small Business Innovation Research (SBIR) Phase II project will address specific technical challenges in the device design to increase the signal-to-noise ratio, expected to increase by a factor of 10. The systems engineering and quality control will also be explored to prepare for translation at scale. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.